Over 11.4% of US children (7.1 million) and 4.4% of adults (10.5 million) are diagnosed with ADHD, with adult female diagnoses surging +140% and co-occurring anxiety or depression affecting 70.0% of patients. While ADHD carries an annual US economic burden of up to $266 billion and drug shortages impacted 44% of patients, 78% of ADHD adults report powerful creative hyperfocus abilities and 34% of tech founders exhibit ADHD traits. The figures below come from empirical research published by the CDC, NIMH, the Lancet Psychiatry, Epic Research, CHADD, and the Journal of Managed Care & Specialty Pharmacy.
TL;DR
- 11.4% of US children aged 3 to 17 (7.1 million) have received an ADHD diagnosis (CDC / NSCH)
- 4.4% of US adults (approx 10.5 million adults) live with active diagnosed ADHD (NIMH)
- Global childhood and adolescent ADHD prevalence stands at 7.2% worldwide (WHO / Lancet)
- Adult female ADHD diagnoses surged by +140% since 2020 due to improved symptom recognition
- 60.0% of adults diagnosed with ADHD were completely undiagnosed during childhood (JAACAP)
- 70.0% of individuals with ADHD experience co-occurring anxiety or depression (NIMH)
- 75.0% of people with ADHD report chronic insomnia and circadian sleep disturbances
- 62.0% of diagnosed ADHD patients receive prescription pharmacological treatments (CDC)
- 44.0% of patients were impacted by nationwide prescription stimulant supply shortages (FDA)
- The total annual economic burden of ADHD in the US ranges from $143 billion to $266 billion
- Average out-of-pocket medical and behavioral care costs reach $2,800 to $4,200 annually per family
- High school students with ADHD graduate at a 68.0% rate vs 84.0% for the general student average
- 34.0% of technology startup entrepreneurs and founders exhibit core ADHD behavioral traits
1. Prevalence Demographics: 7.1M US Children, Adults, and the Female Surge
Attention-Deficit/Hyperactivity Disorder represents one of the most prevalent neurodevelopmental conditions worldwide. The CDC’s National Survey of Children’s Health records that 11.4% of US children (7.1 million) have received a formal ADHD diagnosis.
Adult identification has expanded dramatically: 10.5 million US adults live with ADHD (NIMH), while adult female diagnoses surged +140% (Epic Research) as clinicians recognized masked inattentive presentations historically missed in childhood.
| Metric | Value | Source |
|---|---|---|
| US children aged 3 to 17 diagnosed with ADHD (lifetime diagnosis rate) | 11.4% (approx 7.1M children) | CDC / National Survey of Children’s Health (NSCH) |
| US adult population diagnosed with active Attention-Deficit/Hyperactivity Disorder | 4.4% of adults (approx 10.5M adults) | National Institute of Mental Health (NIMH) |
| Global prevalence of ADHD among children and adolescents worldwide | 7.2% globally | World Health Organization (WHO) / Lancet Psychiatry |
| Boys vs girls childhood ADHD diagnosis ratio (historically skewed, narrowing in adulthood) | 14.5% boys vs 8.0% girls (1.8:1 ratio) | CDC NSCH Report |
| Adult women seeking first-time ADHD evaluations and diagnosis surge since 2020 | +140% increase in adult female diagnoses | Epic Research / JAMA Network Open |
| Adults diagnosed with ADHD who were undiagnosed or overlooked during childhood | 60.0% | Journal of the American Academy of Child & Adolescent Psychiatry |
Speech accessibility tools connect to our speech-to-text statistics. Source: CDC National Survey of Children’s Health.
2. Psychiatric Comorbidities: 70% Anxiety, Depression, and Sleep Disorders
ADHD rarely manifests as an isolated neurodevelopmental condition in clinical practice. NIMH and CHADD data reveal that 70.0% of individuals with ADHD present with at least one co-occurring mental health condition.
Anxiety and sleep disorders are prevalent: 47.0% suffer from Generalized Anxiety Disorder (ADAA), 38.0% experience Major Depression, and 75.0% struggle with severe chronic insomnia and delayed circadian rhythm phases.
| Metric | Value | Source |
|---|---|---|
| ADHD patients presenting with at least one psychiatric co-occurring condition (anxiety, depression) | 70.0% co-morbidity rate | NIMH / CHADD |
| ADHD patients who also experience co-occurring generalized anxiety disorder (GAD) | 47.0% | ADAA / Lancet Psychiatry |
| ADHD individuals diagnosed with clinical major depression | 38.0% | NIMH Clinical Statistics |
| Sleep disturbances and chronic insomnia reported among individuals with ADHD | 75.0% | Sleep Medicine Reviews |
| Neurodivergent individuals with ADHD who also exhibit Autism Spectrum conditions (AuDHD) | 28.0% - 35.0% | Autism Research / CDC |
Sleep duration and circadian metrics connect to our sleep statistics. Source: NIMH Clinical Statistics.
3. Treatment Modalities: Pharmacotherapy, Shortages, and Digital Apps
Clinical management combines stimulant pharmacotherapy, behavioral coaching, and digital therapeutics. The CDC reports that 62.0% of diagnosed patients take prescription medications.
Supply disruptions have created widespread distress: 44.0% of patients were impacted by national prescription shortages (FDA), while 38.0% engage in cognitive executive function coaching and 18.0% use FDA-cleared digital video game therapy.
| Metric | Value | Source |
|---|---|---|
| Diagnosed ADHD patients receiving prescription pharmacological treatment (stimulant/non-stimulant) | 62.0% of diagnosed patients | CDC MMWR / FDA |
| ADHD patients affected by national prescription stimulant shortages (Adderall, Vyvanse) | 44.0% of patients experienced delays | US FDA / DEA National Drug Tracking |
| ADHD individuals receiving behavioral cognitive therapy or executive function coaching | 38.0% | CHADD National Survey |
| Digital therapeutics and FDA-cleared video game therapy adoption for childhood ADHD (e.g., EndeavorRx) | 18.0% of pediatric clinics | American Academy of Pediatrics (AAP) |
Mindfulness and neurological regulation connect to our meditation statistics. Source: U.S. FDA Drug Shortage Database.
4. Socioeconomic Impact: $266B Burden, Out-of-Pocket Costs, and Remote Work
The systemic economic impact of unmanaged executive dysfunction is substantial across healthcare and enterprise sectors. Research in JMCP calculates the total US annual economic burden of ADHD at $143 billion to $266 billion.
Household costs accumulate: families pay $2,800 to $4,200 annually out-of-pocket (CHADD), while 72.0% of neurodivergent professionals state remote work policies dramatically reduce sensory distraction and burnout.
| Metric | Value | Source |
|---|---|---|
| Annual economic burden of ADHD in the United States (lost productivity, healthcare, education) | $143B to $266B annually | Journal of Managed Care & Specialty Pharmacy |
| Average annual out-of-pocket medical and behavioral therapy costs per ADHD family | $2,800 - $4,200/year | CHADD / Health Affairs |
| Adults with ADHD reporting chronic workplace burnout and difficulties with executive dysfunction | 84.0% | CHADD Workplace Survey / SHRM |
| ADHD adults who state remote/flexible hybrid work significantly improved their daily productivity | 72.0% | Neurodiversity in Business Survey |
Professional workplace fatigue connects to our workplace burnout statistics. Source: Journal of Managed Care & Specialty Pharmacy.
5. Academic Outcomes: 68% Graduation Rate and Section 504 Plans
Neurodivergent students require structured classroom accommodations to achieve educational parity. The National Center for Learning Disabilities (NCLD) reports a 68.0% high school graduation rate for students with ADHD (versus 84.0% general average).
Accommodations are critical: 54.0% of public school students with ADHD receive Section 504 plans or IEPs, while ADHD accounts for 32.0% of all registered student disability requests on college campuses (AHEAD).
| Metric | Value | Source |
|---|---|---|
| High school students with ADHD who complete a traditional high school diploma | 68.0% (vs 84.0% general population) | National Center for Learning Disabilities (NCLD) |
| ADHD students receiving formal Section 504 accommodation plans or IEPs in public schools | 54.0% | U.S. Department of Education (ED) |
| College students registered with campus disability services citing ADHD as primary condition | 32.0% of disability registrations | AHEAD (Association on Higher Education And Disability) |
Youth mental well-being connects to our social media mental health statistics. Source: National Center for Learning Disabilities.
6. Neurodiversity Strengths: Divergent Thinking and Startup Founders
Contemporary neuroscience increasingly frames ADHD through the lens of cognitive diversity and specialized adaptive strengths. Harvard Business Review and creativity research show that 78.0% of ADHD adults exhibit high divergent thinking and hyperfocus.
Entrepreneurial correlation is striking: 34.0% of tech startup founders exhibit core ADHD traits (Academy of Management), driving 38.0% of Fortune 500 enterprises to launch targeted neurodiversity recruiting programs.
| Metric | Value | Source |
|---|---|---|
| ADHD adults reporting high levels of creative divergent thinking and hyperfocus capability | 78.0% | Journal of Creative Behavior / Harvard Business Review |
| Entrepreneurs and business founders exhibiting clinically significant ADHD behavioral traits | 34.0% of tech startup founders | Academy of Management Perspectives / Forbes |
| Fortune 500 companies establishing formal neurodiversity hiring and retention programs | 38.0% | Disability:IN / Neurodiversity at Work |
Summary: ADHD by the Numbers
| Metric | Value | Primary Source |
|---|---|---|
| US children diagnosed with ADHD | 11.4% (7.1M kids) | CDC / NSCH Data |
| US adult population with ADHD | 4.4% (10.5M adults) | NIMH Statistics |
| Global childhood ADHD prevalence | 7.2% globally | WHO / Lancet |
| Adult female ADHD diagnosis surge | +140% since 2020 | Epic Research / JAMA |
| Adults overlooked in childhood | 60.0% | JAACAP Study |
| Co-morbidity rate (anxiety/depression) | 70.0% | NIMH / CHADD |
| Sleep disturbances/insomnia in ADHD | 75.0% | Sleep Medicine Reviews |
| Patients on prescription medication | 62.0% | CDC MMWR / FDA |
| Patients affected by drug shortages | 44.0% | US FDA / DEA Tracker |
| Annual US economic burden of ADHD | $143B - $266B | JMCP Economic Study |
| Out-of-pocket family cost per year | $2,800 - $4,200 | CHADD / Health Affairs |
| ADHD workers aiding by remote work | 72.0% | Neurodiversity Survey |
| High school graduation rate for ADHD | 68.0% (vs 84% avg) | NCLD Education Report |
| College disability cases citing ADHD | 32.0% | AHEAD Data |
| ADHD adults citing creative hyperfocus | 78.0% | J of Creative Behavior |
| Tech startup founders with ADHD traits | 34.0% | Academy of Management |
Methodology and Sources
The statistics in this report were compiled from nationwide pediatric health surveys from the CDC NSCH, adult epidemiological registries from NIMH and WHO, clinical cohort datasets from Epic Research and JAMA Network Open, healthcare economic modeling from JMCP, and education benchmarks from the NCLD.
-
Centers for Disease Control and Prevention (CDC) & NSCH: National Survey of Children’s Health: ADHD Diagnosis and Treatment (childhood prevalence, sex ratios, and medication tracking).
-
National Institute of Mental Health (NIMH): Attention-Deficit/Hyperactivity Disorder Statistics & Adult Comorbidities (adult prevalence, co-morbid anxiety, and depression rates).
-
CHADD (Children and Adults with ADHD): National Workplace and Healthcare Economic Surveys (out-of-pocket medical costs, adult burnout, and executive function coaching).
-
Epic Research & JAMA Network Open: Trends in Adult ADHD Diagnosis and Medication Shortage Impact (adult female diagnosis surge and prescription disruption metrics).
-
Journal of Managed Care & Specialty Pharmacy (JMCP): The Economic Burden of ADHD in the United States (lost national economic productivity, healthcare utilization, and education costs).
-
National Center for Learning Disabilities (NCLD) & AHEAD: State of Learning Disabilities and Campus Accommodations (high school graduation gaps, 504 plans, and college registration).
-
Data watch: ADHD statistics reflect clinical diagnoses based on DSM-5 and ICD-11 diagnostic criteria across pediatric and adult cohorts. Self-reported social media identification without clinical evaluation is excluded.
-
Last updated: August 2026. This roundup is updated quarterly as federal CDC surveillance releases, pharmaceutical availability trackers, and psychiatric research journals are published.